Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update
PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) — Predictive Oncology (Nasdaq:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2024, and provided a corporate update. The company reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for the quarter.